Cargando…

Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions

Liver malignant tumors (LMTs) represent a serious adverse drug event associated with drug-induced liver injury. Increases in endocrine-disrupting chemicals (EDCs) have attracted attention in recent years, due to their liver function-inhibiting abilities. Exposure to EDCs can induce nonalcoholic fatt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurosaki, Kota, Uesawa, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301945/ https://www.ncbi.nlm.nih.gov/pubmed/34202146 http://dx.doi.org/10.3390/biom11070944

Ejemplares similares

A Toxicity Prediction Tool for Potential Agonist/Antagonist Activities in Molecular Initiating Events Based on Chemical Structures
por: Kurosaki, Kota, et al.
Publicado: (2020)

Prediction Models for Agonists and Antagonists of Molecular Initiation Events for Toxicity Pathways Using an Improved Deep-Learning-Based Quantitative Structure–Activity Relationship System
por: Matsuzaka, Yasunari, et al.
Publicado: (2021)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Analysis of Corticosteroid-Induced Glaucoma Using the Japanese Adverse Drug Event Reporting Database
por: Kawabe, Ayano, et al.
Publicado: (2023)

Identifying Crude Drugs in Kampo Medicines Associated with Drug-Induced Liver Injury Using the Japanese Adverse Drug Event Report Database: A Comprehensive Survey
por: Kimura, Kyosuke, et al.
Publicado: (2023)

Characterization of the Adverse Effects Induced by Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs Based on the Analysis of the Japanese Adverse Drug Event Report Database
por: Nagai, Junko, et al.
Publicado: (2017)

Analysis of Opioid-Related Adverse Events in Japan Using FAERS Database
por: Hirai, Risako, et al.
Publicado: (2023)

Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database
por: Hosoya, Ryuichiro, et al.
Publicado: (2017)

Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database
por: Toriumi, Shinya, et al.
Publicado: (2021)

Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database
por: Toriumi, Shinya, et al.
Publicado: (2020)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system
por: Fukuda, Akiho, et al.
Publicado: (2017)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
por: Macklis, Paul C., et al.
Publicado: (2020)

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
por: Yamaoka, Kenta, et al.
Publicado: (2022)

Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System
por: Sanagawa, Akimasa, et al.
Publicado: (2018)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

Development of an adverse drug event network to predict drug toxicity
por: Wu, Qier, et al.
Publicado: (2020)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Examination of Risk Factors and Expression Patterns of Atypical Femoral Fractures Using the Japanese Adverse Drug Event Report Database: A Retrospective Pharmacovigilance Study
por: Toriumi, Shinya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_98hbvmm198ncpn5o8jh9e2brso